NVIDIA launches Jetson Thor robotics computers for physical AI systems
Eric W. Roberts, a director and chief business officer at CalciMedica, Inc. (NASDAQ:CALC), recently purchased 4,500 shares of common stock. The transaction, which occurred on June 26, 2025, involved a purchase at a weighted average price of $1.4406 per share, for a total value of $6,482. Prices ranged from $1.43 to $1.4499
Following this transaction, Roberts directly holds 164,706 shares. He also indirectly holds 32,823 shares through FMTC Custodian - Roth IRA FBO Eric W. Roberts, 49,894 shares by Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA, 10,661 shares by IRA Financial Trust Company CFBO Eric W. Roberts, 356,989 shares by Valence Investments SPV IV, LLC, 66,228 shares by Valence Investments SPV V, LLC and 316,109 shares by Valence Investments SPV VI, LLC.
The purchase was reported in a Form 4 filing with the Securities and Exchange Commission. InvestingPro subscribers can access 8 additional key insights about CalciMedica’s financial health, valuation, and market performance to make more informed investment decisions.
In other recent news, CalciMedica reported earnings per share of ($0.33) for the fourth quarter and ($1.22) for the full year 2024. These figures were slightly below H.C. Wainwright’s estimates but exceeded consensus estimates. The company maintains a pro-forma cash balance of approximately $28.4 million, which is expected to support operations into mid-2026. CalciMedica is actively enrolling participants in its Phase 2 KOURAGE trial for acute kidney injury, with results anticipated by the end of 2025. The company also plans to initiate a Phase 3 study for Auxora in treating acute pancreatitis by the end of 2025, pending additional funding. Following a merger, CalciMedica appointed Baker Tilly as its new accounting firm, replacing Moss Adams. The transition was smooth, with no disagreements reported between the company and the former firm. H.C. Wainwright reaffirmed its Buy rating and $16 price target for CalciMedica, citing ongoing clinical developments and financial stability as key factors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.